• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

蛋白质质量控制系统在阿尔茨海默病中的作用和机制。

Roles and Mechanisms of the Protein Quality Control System in Alzheimer's Disease.

机构信息

Department of Nutrition and Food Hygiene, College of Public Health, Zhengzhou University, Zhengzhou 450001, China.

出版信息

Int J Mol Sci. 2021 Dec 29;23(1):345. doi: 10.3390/ijms23010345.

DOI:10.3390/ijms23010345
PMID:35008771
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8745298/
Abstract

Alzheimer's disease (AD) is characterized by the deposition of senile plaques (SPs) and the formation of neurofibrillary tangles (NTFs), as well as neuronal dysfunctions in the brain, but in fact, patients have shown a sustained disease progression for at least 10 to 15 years before these pathologic biomarkers can be detected. Consequently, as the most common chronic neurological disease in the elderly, the challenge of AD treatment is that it is short of effective biomarkers for early diagnosis. The protein quality control system is a collection of cellular pathways that can recognize damaged proteins and thereby modulate their turnover. Abundant evidence indicates that the accumulation of abnormal proteins in AD is closely related to the dysfunction of the protein quality control system. In particular, it is the synthesis, degradation, and removal of essential biological components that have already changed in the early stage of AD, which further encourages us to pay more attention to the protein quality control system. The review mainly focuses on the endoplasmic reticulum system (ERS), autophagy-lysosome system (ALS) and the ubiquitin-proteasome system (UPS), and deeply discusses the relationship between the protein quality control system and the abnormal proteins of AD, which can not only help us to understand how and why the complex regulatory system becomes malfunctional during AD progression, but also provide more novel therapeutic strategies to prevent the development of AD.

摘要

阿尔茨海默病(AD)的特征是老年斑(SPs)的沉积和神经原纤维缠结(NTFs)的形成,以及大脑神经元功能障碍,但实际上,在这些病理生物标志物被检测到之前,患者已经表现出持续的疾病进展至少 10 到 15 年。因此,作为老年人最常见的慢性神经退行性疾病,AD 治疗的挑战在于缺乏有效的早期诊断生物标志物。蛋白质质量控制系统是一组可以识别受损蛋白质的细胞途径,从而调节其周转率。大量证据表明,AD 中异常蛋白质的积累与蛋白质质量控制系统的功能障碍密切相关。特别是在 AD 的早期阶段,已经改变了必需生物成分的合成、降解和去除,这进一步促使我们更加关注蛋白质质量控制系统。该综述主要集中在内质网系统(ERS)、自噬溶酶体系统(ALS)和泛素-蛋白酶体系统(UPS),并深入探讨了蛋白质质量控制系统与 AD 异常蛋白质之间的关系,这不仅有助于我们了解在 AD 进展过程中,复杂的调节系统是如何以及为何变得功能失调的,而且为预防 AD 的发展提供了更具创新性的治疗策略。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/126c/8745298/f36ad5ce988c/ijms-23-00345-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/126c/8745298/e3b9730adbc5/ijms-23-00345-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/126c/8745298/4ab05c8d88c8/ijms-23-00345-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/126c/8745298/df3abf012e7d/ijms-23-00345-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/126c/8745298/72199b6b2bbb/ijms-23-00345-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/126c/8745298/f36ad5ce988c/ijms-23-00345-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/126c/8745298/e3b9730adbc5/ijms-23-00345-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/126c/8745298/4ab05c8d88c8/ijms-23-00345-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/126c/8745298/df3abf012e7d/ijms-23-00345-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/126c/8745298/72199b6b2bbb/ijms-23-00345-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/126c/8745298/f36ad5ce988c/ijms-23-00345-g005.jpg

相似文献

1
Roles and Mechanisms of the Protein Quality Control System in Alzheimer's Disease.蛋白质质量控制系统在阿尔茨海默病中的作用和机制。
Int J Mol Sci. 2021 Dec 29;23(1):345. doi: 10.3390/ijms23010345.
2
The role of ubiquitin proteasomal system and autophagy-lysosome pathway in Alzheimer's disease.泛素蛋白酶体系统和自噬-溶酶体途径在阿尔茨海默病中的作用。
Rev Neurosci. 2017 Nov 27;28(8):861-868. doi: 10.1515/revneuro-2017-0013.
3
Endo-lysosomal pathway and ubiquitin-proteasome system dysfunction in Alzheimer's disease pathogenesis.阿尔茨海默病发病机制中的内体溶酶体途径和泛素蛋白酶体系统功能障碍。
Neurosci Lett. 2019 Jun 11;703:68-78. doi: 10.1016/j.neulet.2019.03.016. Epub 2019 Mar 16.
4
Tau degradation: the ubiquitin-proteasome system versus the autophagy-lysosome system.tau 降解:泛素-蛋白酶体系统与自噬溶酶体系统。
Prog Neurobiol. 2013 Jun;105:49-59. doi: 10.1016/j.pneurobio.2013.03.001. Epub 2013 Mar 23.
5
Impaired autophagy and APP processing in Alzheimer's disease: The potential role of Beclin 1 interactome.阿尔茨海默病中自噬和 APP 处理受损:Beclin 1 相互作用组的潜在作用。
Prog Neurobiol. 2013 Jul-Aug;106-107:33-54. doi: 10.1016/j.pneurobio.2013.06.002. Epub 2013 Jul 1.
6
The Ubiquitin System in Alzheimer's Disease.阿尔茨海默病中的泛素系统。
Adv Exp Med Biol. 2020;1233:195-221. doi: 10.1007/978-3-030-38266-7_8.
7
Modulation of AβPP and GSK3β by Endoplasmic Reticulum Stress and Involvement in Alzheimer's Disease.内质网应激对淀粉样前体蛋白和糖原合成酶激酶3β的调节及其与阿尔茨海默病的关系
J Alzheimers Dis. 2017;57(4):1157-1170. doi: 10.3233/JAD-161111.
8
Decrease of neuronal FKBP4/FKBP52 modulates perinuclear lysosomal positioning and MAPT/Tau behavior during MAPT/Tau-induced proteotoxic stress.神经元 FKBP4/FKBP52 的减少调节了 MAPT/Tau 诱导的蛋白毒性应激过程中核周溶酶体的定位和 MAPT/Tau 的行为。
Autophagy. 2021 Nov;17(11):3491-3510. doi: 10.1080/15548627.2021.1875611. Epub 2021 Jan 25.
9
Alzheimer's disease and the autophagic-lysosomal system.阿尔茨海默病与自噬-溶酶体系统
Neurosci Lett. 2019 Apr 1;697:49-58. doi: 10.1016/j.neulet.2018.05.017. Epub 2018 May 18.
10
Autophagic dysfunction in Alzheimer's disease: Cellular and molecular mechanistic approaches to halt Alzheimer's pathogenesis.阿尔茨海默病中的自噬功能障碍:阻止阿尔茨海默病发病机制的细胞和分子机制方法。
J Cell Physiol. 2019 Jun;234(6):8094-8112. doi: 10.1002/jcp.27588. Epub 2018 Oct 26.

引用本文的文献

1
Chaperone-Mediated Responses and Mitochondrial-Endoplasmic Reticulum Coupling: Emerging Insight into Alzheimer's Disease.伴侣介导的反应与线粒体-内质网偶联:对阿尔茨海默病的新见解
Cells. 2025 Jul 31;14(15):1179. doi: 10.3390/cells14151179.
2
Meta-Analysis of Transcriptomic Studies of Blood and Six Brain Regions Identifies a Consensus of 15 Cross-Tissue Mechanisms in Alzheimer's Disease and Suggests an Origin of Cross-Study Heterogeneity.血液和六个脑区转录组学研究的荟萃分析确定了阿尔茨海默病中15种跨组织机制的共识,并揭示了跨研究异质性的根源。
Am J Med Genet B Neuropsychiatr Genet. 2025 Jun;198(4):e33019. doi: 10.1002/ajmg.b.33019. Epub 2024 Dec 16.
3

本文引用的文献

1
Iron Homeostasis Disorder and Alzheimer's Disease.铁代谢失衡与阿尔茨海默病
Int J Mol Sci. 2021 Nov 18;22(22):12442. doi: 10.3390/ijms222212442.
2
Current druggable targets for therapeutic control of Alzheimer's disease.用于治疗阿尔茨海默病的可药物靶标。
Contemp Clin Trials. 2021 Oct;109:106549. doi: 10.1016/j.cct.2021.106549. Epub 2021 Aug 28.
3
Pathogenesis and promising therapeutics of Alzheimer disease through eIF2α pathway and correspondent kinases.阿尔茨海默病通过 eIF2α 通路和相应激酶的发病机制和有前途的治疗方法。
A Cationic Zn-Phthalocyanine Turns Alzheimer's Amyloid β Aggregates into Non-Toxic Oligomers and Inhibits Neurotoxicity in Culture.
一种正电荷锌酞菁将阿尔茨海默病淀粉样β聚集物转化为无毒低聚物并在培养物中抑制神经毒性。
Int J Mol Sci. 2024 Aug 16;25(16):8931. doi: 10.3390/ijms25168931.
4
Neuropathogenesis-on-chips for neurodegenerative diseases.神经退行性疾病的类脑芯片研究进展
Nat Commun. 2024 Mar 12;15(1):2219. doi: 10.1038/s41467-024-46554-8.
5
Higher angiotensin-converting enzyme 2 (ACE2) levels in the brain of individuals with Alzheimer's disease.阿尔茨海默病患者大脑中的血管紧张素转换酶 2(ACE2)水平更高。
Acta Neuropathol Commun. 2023 Oct 2;11(1):159. doi: 10.1186/s40478-023-01647-1.
6
Pharmacological importance of Kunxian Capsule in clinical applications and its adverse effects: A review.昆仙胶囊在临床应用中的药理重要性及其不良反应:综述
Chin Herb Med. 2023 Mar 8;15(2):222-230. doi: 10.1016/j.chmed.2022.08.011. eCollection 2023 Apr.
7
Exploring Whether Iron Sequestration within the CNS of Patients with Alzheimer's Disease Causes a Functional Iron Deficiency That Advances Neurodegeneration.探索阿尔茨海默病患者中枢神经系统内的铁螯合是否会导致功能性铁缺乏,进而促进神经退行性变。
Brain Sci. 2023 Mar 18;13(3):511. doi: 10.3390/brainsci13030511.
8
Autophagy-related gene and protein expressions during blastocyst development.囊胚发育过程中自噬相关基因和蛋白的表达。
J Assist Reprod Genet. 2023 Feb;40(2):323-331. doi: 10.1007/s10815-022-02698-4. Epub 2022 Dec 28.
9
Tau kinetics in Alzheimer's disease.阿尔茨海默病中的 Tau 动力学
Front Aging Neurosci. 2022 Nov 9;14:1055170. doi: 10.3389/fnagi.2022.1055170. eCollection 2022.
10
A Tau Pathogenesis-Based Network Pharmacology Approach for Exploring the Protections of in Alzheimer's Disease.一种基于 Tau 蛋白致病机制的网络药理学方法用于探索在阿尔茨海默病中的保护作用。
Front Pharmacol. 2022 Apr 21;13:877806. doi: 10.3389/fphar.2022.877806. eCollection 2022.
Metab Brain Dis. 2020 Dec;35(8):1241-1250. doi: 10.1007/s11011-020-00600-8. Epub 2020 Jul 17.
4
Molecular Mechanisms of ER Stress and UPR in the Pathogenesis of Alzheimer's Disease.阿尔茨海默病发病机制中内质网应激和未折叠蛋白反应的分子机制。
Mol Neurobiol. 2020 Jul;57(7):2902-2919. doi: 10.1007/s12035-020-01929-y. Epub 2020 May 19.
5
Current and Future Treatments in Alzheimer Disease: An Update.阿尔茨海默病的当前及未来治疗方法:最新进展
J Cent Nerv Syst Dis. 2020 Feb 29;12:1179573520907397. doi: 10.1177/1179573520907397. eCollection 2020.
6
Activating transcription factor 6 reduces Aβ1-42 and restores memory in Alzheimer's disease model mice.激活转录因子 6 减少 Aβ1-42 并恢复阿尔茨海默病模型小鼠的记忆。
Int J Neurosci. 2020 Oct;130(10):1015-1023. doi: 10.1080/00207454.2020.1715977. Epub 2020 Jan 21.
7
Atf6α impacts cell number by influencing survival, death and proliferation.ATF6α 通过影响细胞的存活、死亡和增殖来影响细胞数量。
Mol Metab. 2019 Sep;27S(Suppl):S69-S80. doi: 10.1016/j.molmet.2019.06.005.
8
Traditional Oriental Medicines and Alzheimer's Disease.传统东方医学与阿尔茨海默病
Aging Dis. 2019 Apr 1;10(2):307-328. doi: 10.14336/AD.2018.0328. eCollection 2019 Apr.
9
An update on the interactions between Alzheimer's disease, autophagy and inflammation.阿尔茨海默病、自噬和炎症之间相互作用的最新研究进展。
Gene. 2019 Jul 15;705:157-166. doi: 10.1016/j.gene.2019.04.040. Epub 2019 Apr 25.
10
Learning and memory deficits and alzheimer's disease-like changes in mice after chronic exposure to microcystin-LR.长期暴露于微囊藻毒素-LR 后,小鼠出现学习和记忆缺陷及类似阿尔茨海默病的变化。
J Hazard Mater. 2019 Jul 5;373:504-518. doi: 10.1016/j.jhazmat.2019.03.106. Epub 2019 Mar 26.